Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 21.00p 20.50p 21.50p 21.00p 21.00p 21.00p 85,138 07:38:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.2 -6.7 -4.1 - 43.75

Amryt Pharma Share Discussion Threads

Showing 1476 to 1500 of 1500 messages
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
DateSubjectAuthorDiscuss
16/8/2017
15:44
The last 4 trades have all been buys, though volume so far today has been very low. 4 consecutive buys; wonders will never cease! Though whoever bought just 50 shares @ 12.07 @ 21.275p was hardly pushing the boat out! That cost £10.64p. Surely the commission would approximetely double the cost per share to over 40p. Perhaps they meant to order a bigger amount, such as 5,000 shares and left a couple of zeros off when buying online? PS. The share price is going sideways and consequently the Bollinger Bands are getting very, very, tight ("necking"). The 20 day, 50 day & 200 days EMA's are almost concurrent (almost overlapping). The last time all that happened on the chart, early this year, the share price went from circa 18p to circa 28p in less than a month. The AMYT share price is, IMO, based on the chart, due for another big movement on the next news (probably the interims in mid September?). The big question is; will the big movement be up, or down? My money is on the former, which is the reason I continue to hold all of my AMYT shares. Only time will tell whether my decision is correct
papillon
16/8/2017
13:04
"I don't know the actuals myself". NOR DO I MATEY!! Only the company and health professionals working in that particular field can know the possible answers to those questions, pottermagic. Presumably AMYT will know all those "actuals", pottermagic and will factor them into their revenue forecasts? One would hope so! PS. I HAVEN'T considered all those "actuals" myself, pottermagic. Why should I? Like yourself I haven't the expertise, or knowledge, to answer the questions you pose. Perhaps you should have gone to the AGM and asked those questions of AMYT rather than asking me; they would likely have had both the expertise and knowledge to answer them!
papillon
16/8/2017
12:42
Have you considered what the Market saturation point might be for Sales of this stuff, in the target Markets ? Have you considered the timescales involved for continuous/regular use with Patients and replenishment cycles ? What if we saturated the target Market with volumes equal to or greater than typical use cycles, such that replenishment (repeat Sales) only come once per annum ? That might mean we've witnessed a peak already and should only expect repeat Sales to fairly lengthy cycles !! I don't know the actuals myself but all of the above has crossed my Mind.
pottermagic2310
15/8/2017
22:55
Do you think that is likely to indicate that there won't be a 'better than expected' result in the interims? I was hopeful that the sales would exceed the original target of €10m and also set a positive projection for the remainder of the year. I agree, we'll need something more than what was already reported back in May. We'll see I guess but I remain optimistic that they'll produce the goods. Otherwise we could be going back to sleep for a considerably long time! Haha
greendragon777
15/8/2017
22:27
Well, greendragon, AMYT re-iterated the 10.5m Euro 2017 forecast for LOJUXTA revenue on the 25th May (They had originally given that forecast in the Final Results RNS). That forecast must have been based on their sales figures for LOJUXTA in December, January, February, March, April and part of May in their sales area and the sales figures for JUXTAPID in the USA would have had no impact on AMYT's forecast, so I think we can safely ignore Novelion's possible problems with Medicare in the USA. I think we will need more than a re-iteration of that 10.5m Euro forecast in the interim results RNS to push up the share price above this years highs. Fingers crossed we get that good news.
papillon
15/8/2017
18:08
Haha.....exactly Paps we just need a little inside information, it's not like we're asking for too much! :-) Thanks for the info above Papillon, much appreciated. I guess it's a reminder that we are in a high risk asset class investing in Pharma shares, but equally we love those extra high returns when they come! ;-) T Minus 3 to 4 weeks and counting.......
greendragon777
15/8/2017
17:03
Though Novelion had what appears to be an excellent 2nd quarter (sales of it's both of it's drugs were up on the 1st quarter: MYALEPT up by 28% & JUXTAPID up 29%) the Market expected more, greendragon and was disappointed by the results hence the big percentage drop in the share price when the results were announced. Consequently both drugs had their revenue forecasts for 2017 reduced: "2017 Financial Guidance The Company is revising its previously stated net revenues financial guidance for full year 2017 and now expects: Total net revenues between $135 million and $145 million, compared to the prior range of between $155 million and $165 million; MYALEPT net revenues between $65 million and $70 million, compared to the prior range of between $75 million and $80 million; and JUXTAPID net revenues between $70 million and $75 million, compared to the prior range of between $80 million and $85 million." Novelion state the risk factors associated with their JUXTAPID forecast for 2017: "the risk that net revenues for JUXTAPID in the U.S. may be negatively impacted by Medicare patients not being able to afford JUXTAPID" I saw a report today that a couple in Manhatton, New York, had leapt to their deaths from a high rise tower block because they couldn't afford their prescription drugs! The USA is Novelion's main market by far for JUXTAPID. There are also possible concerns (such as regulatory concerns) in it's markets outside of the USA like Brazil & Japan. Let's hope none of the above fears will adversely affect the forecast for LOJUXTA sales in 2017 made in May (?) by AMRYT! Fingers crossed! Obviously LOJUXTA is targeting very different markets to JUXTAPID. Would be nice if we also got some good news contained in the interims unrelated to LOJUXTA. Fingers crossed. Oh to be a fly on the wall in the AMYRT boardroom discussing the interim results! hTTp://ir.novelion.com/releasedetail.cfm?ReleaseID=1036424
papillon
15/8/2017
12:20
Yikes, that was a pretty big drop for Novelion. Hopefully AMYT will do it's own thing though with a positive set of results. There is still circa 4 weeks left for the results to be announced so it could still tick up in the run up to that....maybe the last week in August or the first week in Sept, we'll see. Hopefully we're going through the last bit of pain before the bounce! :-)
greendragon777
15/8/2017
11:59
Well the market didn't like the recent Nasdaq listed Novelion 2nd quarter results (issued 8th August), as there was a fall in the share price from $9.15 to $7.59 over the following 3 days, because revenue projections for 2017 were scaled back. Lets hope that AMYT's results please our market! Fingers crossed! AMYT is a binary bet from here until the results are issued. A good news update and the share price rises, bad news update and it falls. Bollinger Bands are "necking" as the share price goes sideways pre the results RNS. My hopes of a rise towards 27p pre the results has, unfortunately, turned out to be so much pie in the sky! In this market biotechs and O&G explorers sp's don't rise just prior to an RNS being released! hTTp://stockcharts.com/h-sc/ui?s=nvln
papillon
14/8/2017
19:01
Nice one Papillon, hopefully this will draw a line under the recent sliding and the start of the buyers coming into the market as you say ahead of the interims. This is a time to hold our nerve and get ready for the journey back up....we'll get there Paps, we'll get there!! ;-)
greendragon777
14/8/2017
16:42
Tick up at the end, greendragon. Not based on today's trades, which have all been sells. A late reported buy, to be announced after market has closed? Hopefully the buying pressure, from now on, will eclipse the selling pressure. Fingers crossed, as always! PS. I don't trust the advfn chart as the historic intraday candlesticks are always wildly incorrect. I use the M oneyAM chart and that shows a bounce today off the lower Bollinger Band, which appears to be acting as support.
papillon
14/8/2017
12:46
Hmmmm, we could do without those sell offs Paps but as you say hopefully it's not related to any special knowledge. It's probably the last of the shakeout before she rises back up to a level that more reflects the underlying value of this company. Just a few more weeks Paps.....hang in there! :-)
greendragon777
14/8/2017
12:06
A large 100,000 sell @ 20.50p reported this morning (OK trade). That follows on from a 50,000 sell (another OK trade) late Friday afternoon. Lets hope the seller(s) don't know anything we don't know! LOL. Lets hope the selling is coming to an end and we start to see some big buying for a change! Fingers crossed!
papillon
14/8/2017
12:02
moneytree1 13 Aug '17 - 08:51 - 1362 of 1363 0 0 runway called this well @26p..... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> He did. PS. Luckily I'm not showing a loss on AMYT, but I regret recently topping up at 22p (and not selling @ 27p, like Jacksonpollack!). The chart didn't lie. The failure to break above the 27p closing high in June (it closed at 26.50p) was a strong indicator that the AMYT share price was going down in the short term.
papillon
13/8/2017
13:41
Read today's Times, Business, bottom of page 7 "Niche busters....." AMYT not mentioned but brilliant article nevertheless. Cheers!
bazworth
13/8/2017
08:51
runway called this well @26p.....
moneytree1
12/8/2017
17:37
That would certainly hurt if it fell to 15p Paps but with the interims getting close all the while I would be very surprised if it did. As you said it's all on very thin volumes and even a handful of decent buyers would reverse the trend to head back up again very quickly. This is a time for holding on tight and we'll get out the other side very soon hopefully. If/when she takes a decent jump back up, I might even consider joining the other bb and call Congemi out on it! If it goes the other way, I guess we'll have to lay low here for a bit longer! haha
greendragon777
12/8/2017
17:16
The only thing that worries me, greendragon, is the AMYT chart. A bearish double top could have formed. Possible target share price is circa 15p. Will it happen? I don't know!! I hope not! Fingers crossed!! Unfortunately there is almost a complete absence of buyers at the moment. Perhaps that will change? Who knows? Hopefully support @ circa 20p holds, if tested. Double tops are fairly reliable chat patterns, but obviously not always accurate. I'd hate to see Congemi, on the lse bb, proved right with his 14p share price target!
papillon
12/8/2017
17:16
The only thing that worries me, greendragon, is the AMYT chart. A bearish double top could have formed. Possible target share price is circa 15p. Will it happen? I don't know!! I hope not! Fingers crossed!! Unfortunately there is almost a complete absence of buyers at the moment. Perhaps that will change? Who knows? Hopefully support @ circa 20p holds, if tested. Double tops are fairly reliable chat patterns, but obviously not always accurate. I'd hate to see Congemi, on the lse bb, proved right with his 14p share price target!
papillon
12/8/2017
11:54
Nice bit of info there Paps, that's exactly the type of news we're hoping for next month and certainly bodes well for potential european sales. Hopefully it will be 2 fold when AMYT report their results. 1. The sales to date exceed original estimates and 2. The projected sales for the next 6 to 12 months exceed early estimates too. Not sure how much news they'll be able to provide in relation to AP101 but even if they can give some sort assurance that it's progressing well, that should have a positive impact on the share price too. Don't worry Paps, you won't be kicking yourself when it jumps 50% over the coming months! 😉
greendragon777
12/8/2017
09:45
Novelion results for the 2nd Quarter of 2017 released 8th August: hTTp://ir.novelion.com/releasedetail.cfm?ReleaseID=1036424 JUXTAPID (LOJUXTA) had an excellent quarter. Sales up 29% on the previous quarter: "JUXTAPID: Novelion reported net revenues of JUXTAPID of $20.7 million in the second quarter of 2017, $11.1 million, or 54%, of which were from prescriptions written in the U.S. This represents sequential global growth of 29% from the first quarter of 2017." It would be nice if LOJUXTA was exhibiting similar excellent sales growth to JUXTAPID in it's large selling area (EEC countries population alone is over 500 million)! Fingers crossed. EDIT. Someone (Tuchenhagen) on the lse bb has stated that Novelion is "not flush with money for more trials". Yet the 2nd Quarter results for Novelion (dated 8th August) state that: "Novelion ended the second quarter of 2017 with $83.3 million in unrestricted cash, compared with $84.8 million at the end of the first quarter of 2017." $83.3 million in unrestricted cash! Doesn't sound to me as though they are skint! You do get some uniformed posters on the lse bb. Perhaps someone could post the above information on the lse bb for the education of Tuchenhagen and Congemi.
papillon
11/8/2017
14:22
It's currently "resting" on the lower Bollinger Band, greendragon. That will likely act as support? We shall see. It's drifting down today on miniscule volume. Still annoyed with myself for topping up too early! PS The upper Bollinger Band is currently at 23p. I suspect (hope?) that those small shareholders who have sold today and within the last few weeks will be kicking themselves for selling when the interim results RNS is issued!
papillon
11/8/2017
13:17
Don't worry Paps, the top up price will pale into insignificance when she starts to break out. The dilemma then will be when to get out.....do you take a 30,40,50,100,200 or 500% profit....nice little dilemma to find yourself in (all going well of course!) Mid September can't come quick enough at this stage....I need to get back into green territory, I'm seeing too much red at the moment! Haha It's not causing any pain though so it's all good! On a more positive note, my most volatile asset class, Cryptos, have been on a straight line upwards recently (I mostly hold IOTA) since the BTC fork. I think investors are waking up to the fact that IOTA is a really good technology....let's hope the bull run continues. Just need AMYT to follow suit. I do love my risky trades does GreenDragon! Haha Only a few weeks to go now Paps and we'll know our fate....buckle up, it could be a bumpy ride! :-)
greendragon777
11/8/2017
11:50
papillon 23 Jul '17 - 15:29 - 1320 of 1353 0 0 Edit AMYT share price currently going sideways between 21p-28p. A rectangle chart pattern. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I should have taken my own advice and waited until the mid price dropped to 21p and then had my small top up! Instead I bought last week at 22p; if I'd waited until today I could have bought at 21p (buy went through today just below the 21p mid price). LOL.
papillon
09/8/2017
14:48
Thanks for the link BWD. As Papillon said, maybe no harm in posting it up on the LSE BB. This Congemi character seems to make sweeping claims based on little evidence (unless he had some evidence somewhere?) Paps, I agree 100% that it's much more likely to move upwards than down with the Interims pending and as we get closer to that date. Unless there is some tragic news contained within we should start to move north. The only ones asleep are us, while we await the results.....it certainly isn't the management at AMYT! haha
greendragon777
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170816 15:21:08